1.70Open1.70Pre Close0 Volume9 Open Interest11.00Strike Price0.00Turnover166.64%IV7.00%PremiumJan 17, 2025Expiry Date1.00Intrinsic Value100Multiplier22DDays to Expiry0.70Extrinsic Value100Contract SizeAmericanOptions Type-0.5070Delta0.0964Gamma4.44Leverage Ratio-0.0362Theta-0.0040Rho-2.25Eff Leverage0.0099Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet